Immunotherapy targeting cancer fusion protein may hold key to treating rare liver cancer

Mar 19, 2024 | Immunology

Fibrolamellar carcinoma (FLC) is a rare liver cancer with a poor prognosis if not addressed early with surgery. The disease is caused by a single genetic mutation that creates a fusion protein. Scientists at St. Jude Children’s Research Hospital and The University of Tennessee Health Science Center discovered an immune cell protein that can target and spark the destruction of FLC.